Payment overview · 2025
General Payments
$1,168.07
74 reported records · 15 companies
Healthcare provider profile · identity verified
Robert T Chambers, MD
Allopathic & Osteopathic Physicians|Family Medicine · KNOXVILLE, TN · NPI 1619911039
Verified facts
What the public records show
CMS Open Payments records show Robert T Chambers, MD received $1,168.07 in general payments during 2025 across 74 reported records.
Novo Nordisk Inc accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $270.17 | 23.1% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.38 | 16.4% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.37 | 14.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.45 | 9.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.10 | 8.8% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.74 | 7.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.04 | 3.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.98 | 3.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.39 | 3.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.29 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.46 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.27 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.25 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.73 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.45 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,168.07 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $191.38 | 24 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $191.38 | 24 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $176.78 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $159.30 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $90.89 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $88.95 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $88.95 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $88.95 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.74 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.29 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.90 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.90 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
63 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
40 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 97 |
| Lisinopril | Lisinopril | 266 | 81 |
| Gabapentin | Gabapentin | 235 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 52 |
| Famotidine | Famotidine | 152 | 55 |
| Alendronate Sodium | Alendronate Sodium | 147 | 44 |
| Metformin Hcl | Metformin Hcl | 135 | 36 |
| Metformin Hcl Er | Metformin Hcl | 133 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 121 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 34 |
| Losartan Potassium | Losartan Potassium | 112 | 28 |
| Ezetimibe | Ezetimibe | 103 | 28 |
| Alprazolam | Alprazolam | 98 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 25 |
| Omeprazole | Omeprazole | 89 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 26 |
| Potassium Chloride | Potassium Chloride | 84 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 20 |
| Trazodone Hcl | Trazodone Hcl | 77 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 16 |
| Valsartan | Valsartan | 76 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | suppressed |
| Ozempic | Semaglutide | 70 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 15 |
| Irbesartan | Irbesartan | 66 | 15 |
| Glipizide | Glipizide | 65 | 20 |
| Atenolol | Atenolol | 64 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 63 | 63 |
| Eliquis | Apixaban | 57 | 15 |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Montelukast Sodium | Montelukast Sodium | 56 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 23 |
| Benazepril Hcl | Benazepril Hcl | 51 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 16 |
| Tramadol Hcl | Tramadol Hcl | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 12 |
| Furosemide | Furosemide | 43 | 15 |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 14 |
| Meloxicam | Meloxicam | 42 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 40 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 18 |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Finasteride | Finasteride | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Prednisone | Prednisone | 15 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,168.07 · 74 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BodyGuardian, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Kerendia, Korlym, LEQVIO, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error